Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. by Russell, R, Watts, N, Ebetino, F, Rogers, M

NE10790, a phosphonocarboxylate analogue of risedronate, induces human myeloma cell apoptosis in vitro by Roelofs, A, Russell, R, Ebetino, F, Shipman, C

Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis. by Pazianas, M, Cooper, C, Ebetino, F, Russell, R

The Successful Design Of A Novel Highly Potent Nitrogen-Containing Bisphosphonate With Lower Bone Affinity. by Ebetino, F, Ebetino, F, Lundy, M, Kwaasi, A, Dunford, J, Duan, X, Triffitt, J, Mazur, A, Jeans, G, Barnett, B, Russell, R

Differentiation of bisphosphonates based on their physical chemical properties by Phipps, R, Ebetino, F, Barnett, B, Xia, Z, Russell, R

A computational model explains bisphosphonate binding affinity differences on hydroxyapatite by Ebetino, F, Barnett, B, Russell, R, Henneman, Z, Nancollas, G

A computational model explains bisphosphonate binding affinity differences on hydroxyapatite by Ebetino, F, Barnett, B, Russell, R, Henneman, Z, Nancollas, G

Bisphosphonates: Mechanisms of Action by Roelofs, A, Ebetino, F, Reszka, A, Russell, R, Rogers, M

Studies to elucidate the anti-tumor mechanism of action of risedronate in human myeloma cells; Use of an analogue of risedronate reveals the effects of differential inhibition of p... by Roelofs, A, Hulley, P, Russell, R, Ebetino, F, Rogers, M

Bisphosphonate binding affinity as assessed by inhibition of carbonated apatite dissolution in vitro. by Henneman, Z, Nancollas, G, Ebetino, F, Russell, R, Phipps, R

Mineral binding affinities and zeta potentials of bisphosphonates by Nancollas, G, Tang, R, Gulde, S, Ebetino, F, Phipps, R, Russell, R

Kinetic analysis of conformational changes in farnesyl pyrophosphate synthase induced by nitrogen containing bisphosphonates by Dunford, J, Kavanagh, K, Rogers, M, Opperinann, U, Ebetino, F, Russell, R

Apomine enhances the antitumor effects of lovastatin on myeloma cells by down-regulating 3-hydroxy-3-methylglutaryl-coenzyme A reductase. by Roelofs, A, Edwards, C, Russell, R, Ebetino, F, Rogers, M, Hulley, P

Investigations into the kinetic mechanism of inhibition of farnesyl diphosphate synthase by nitrogen containing bisphosphonates by Dunford, J, Kavanagh, K, Oppermann, U, Ebetino, F, Russell, R, Rogers, M

Risedronate, and its phosphonocarboxylate analogue NE10790, both induce apoptosis, but have differential effects on the cell cycle and protein prenylation in human myeloma cells. by Roelofs, A, Hulley, P, Russell, R, Ebetino, F, Rogers, M, Shipman, C

Selective inhibition of Rab prenylation by a phosphonocarboxylate analogue of risedronate induces apoptosis, but not S-phase arrest, in human myeloma cells. by Roelofs, A, Hulley, P, Meijer, A, Ebetino, F, Russell, R, Shipman, C

BISPHOSPHONATES AFFECT HUMAN OSTEOCLAST DEVELOPMENT IN VITRO by Mabilleau, G, Kwaasi, A, Sabokbar, A, Tsoumpra, M, Ebetino, F, Russell, R

Refining the use of hydroxyapatite column chromatography to reveal differences in relative binding affinities of bisphosphonates by Lawson, M, Xia, Z, Triffitt, J, Ebetino, F, Phipps, R, Russell, R

The use of hydroxyapatite column chromatography as a novel method to reveal differences in relative binding affinities of bisphosphonates by Lawson, M, Triffitt, J, Ebetino, F, Phipps, R, White, D, Russell, R

Bisphosphonate bone affinity, differences predicted by in vitro binding to carbonated apatite by Henneman, Z, Tang, R, Gulde, S, Nancollas, G, Phipps, R, Russell, R, Ebetino, F